Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Hims & Hers Health Inc (NY: HIMS )

24.15 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Hims & Hers Health Inc

< Previous 1 2 3 4 5 Next >
Hims & Hers Expands Nutrition Support to Fuel Customers’ Weight Loss Journeys
From Hims & Hers
Via Business Wire
Hims & Hers Appoints Tenured Pharmaceutical, Regulatory, and Quality Experts to Key Leadership Positions
From Hims & Hers
Via Business Wire
Americans Continue to Struggle to Access Branded GLP-1s as Shortages Continue
From Hims & Hers
Via Business Wire
Hims & Hers Health, Inc. Reports Third Quarter 2024 Financial Results
From Hims & Hers
Via Business Wire
How Compounded Treatments Are Helping Hims & Hers Customers Meet Their Weight Loss Goals
From Hims & Hers
Via Business Wire
Top 3 Stocks Institutions Are Buying Right Now
Despite the stock market trading at new all-time highs, institutions still find enough reason to buy more enormous stakes in three stocks. 
Via MarketBeat
Hims & Hers names Dr. Jessica Shepherd as Chief Medical Officer of Hers
From Hims & Hers
Via Business Wire
Hims & Hers to Announce Third Quarter 2024 Financial Results on November 4, 2024
From Hims & Hers
Via Business Wire
Top 3 Stocks with Explosive Call Option Activity: What to Watch
Three stocks reported a surge in call option buying recently, showing investors that there could be a path to more upside potential, analysts agree 
Via MarketBeat
Hims & Hers Stock Joins S&P 600: Is More Upside on the Horizon?
There is now a new reason to look into Hims & Hers stock for additional upside, including the new addition to the S&P 600 index alongside double-digit growth. 
Via MarketBeat
Topics Stocks
Exposures US Equities
Hims & Hers to Offer Access to Compounded GLP-1 Injections for as Low as $99/Month to U.S. Military, Veterans, Teachers, Nurses and First Responders
From Hims & Hers
Via Business Wire
Invest While You Can: Pullbacks on These 3 Stocks Won’t Last Long
Three stocks stand out for investors to consider as they recently had big selloffs. There are fundamental reasons to believe that these discounts won't last 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Top 3 Stocks to Watch: Options Traders Bet on Big Gains
Three stocks have stood out for call option traders to bet on in the coming months as a view for a recovery rally after an S&P 500 sell-off last week 
Via MarketBeat
Topics Stocks
Exposures US Equities
MarketBeat Week in Review – 8/5 - 8/9
Stocks were looking for direction to end the week, but next week may bring more volatility with the latest reading on inflation and the start of retail earnings 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Hims & Hers Reports Stellar Quarter: Stock Set for a Rally
Hims & Hers stock is showing the market why its fair value is double-digits above where it trades today, with Wall Street analysts to agree 
Via MarketBeat
Topics Bonds ETFs
Exposures Debt Markets
Hims & Hers Health, Inc. Reports Second Quarter 2024 Financial Results
From Hims & Hers
Via Business Wire
Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Hims & Hers stock is looking like a worthy dip to watch in the coming months, especially as its decline had nothing to do with company operations 
Via MarketBeat
Can the New CEO Revive This Struggling Telehealth Stock?
Virtual healthcare provider Teladoc Health Inc. (NYSE: TDOC) stock is trading down 57.8% year-to-date (YTD). The collapse occurred after reporting Q4 2023 
Via MarketBeat
Topics Earnings
Exposures Financial
Pharmaceutical Industry Chief Kåre Schultz Joins Hims & Hers Board
From Hims & Hers
Via Business Wire
Is This Telehealth Stock a Buy After the Recent Pullback?
Hims & Hers Health leverages telehealth's accessibility to disrupt traditional healthcare and deliver personalized wellness solutions. 
Via MarketBeat
Hims & Hers to Announce Second Quarter 2024 Financial Results on August 5, 2024
From Hims & Hers
Via Business Wire
Eli Lilly's Stock Surge Driven by GLP-1 Demand
Shares of Eli Lilly stock are about to hit a new all-time high, sponsored by the pending approval of new weight loss drugs 
Via MarketBeat
Topics Economy
Exposures Interest Rates
3 Sector Stars Lead Growth: Foot Locker, Shake Shack, Hims & Hers
These three stocks are looking to get a chunk of the total added jobs in the economy, meaning that analyst double-digit upside and growth projections are real 
Via MarketBeat
Topics Economy
Exposures Economy
MarketBeat Week in Review – 6/3 - 6/7
Equity markets shrugged off a much hotter-than-expected jobs report, but there could be more volatility after the next readings on inflation come out next week 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Hims & Hers Health Soars on Generic GLP-1 Rollout Plans
Him & Hers Health Inc. (NYSE: HIMS) provides a direct-to-consumer (DTC) health and wellness platform. The company was best known for prescribing treatments 
Via MarketBeat
Call Option Volumes Spiked For These 3 Stocks
Option traders decided to plow into call contracts for these three stocks, investors can see the specific fundamental reasons behind this decision 
Via MarketBeat
LifeMD Can Surge on Its GLP-1 Offerings
LifeMD is a leading telehealth provider that investors should take note of; the company is entering the GLP-1 market, and its stock could soar as a result 
Via MarketBeat
Hims & Hers Announces Access to GLP-1 Injections, Passing Cost Savings Onto Customers
From Hims & Hers
Via Business Wire
Hims & Hers Welcomes Anja Manuel, Foreign Policy Expert, Domestic Regulations Advisor, and Former Diplomat to its Board of Directors
From Hims & Hers
Via Business Wire
3 Stocks That Suddenly Drew in Options Traders
Three discounted stocks caught the attention of call option buyers last week, and they have Wall Street analysts to back them through double-digit upside. 
Via MarketBeat
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.